The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma
Completed
- Conditions
- Sarcoma, Ewing
- Interventions
- Other: patients
- Registration Number
- NCT05100368
- Lead Sponsor
- Istituto Ortopedico Rizzoli
- Brief Summary
Extraction of laboratory data from blood tests prior to surgical and chemotherapy and other histological, clinical and instrumental data related to the patient's history from the digitized medical Digitized medical records and analysis of the same. The medical records of 1000 patients from January 1, 2000, until December 31, 2020
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis;
- Patients with age ≥ 2 years;
- Minimum follow-up duration of 2 years;
- Medical records, complete blood work and instrumental examinations; Regular follow-up.
Exclusion Criteria
- Patients with Ewing's sarcoma or osteosarcoma who have received medical treatment (surgery radiotherapy or chemotherapy) in other institutions prior to admission to the Rizzoli Orthopaedic Institute.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients patients Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis
- Primary Outcome Measures
Name Time Method 5-year survival at baseline (Day0) Evaluation of 5-year survival in relation to histologic, laboratory, clinical, and instrumental laboratory, clinical and instrumental factors
- Secondary Outcome Measures
Name Time Method Rate of local recurrence at baseline (Day0) Evaluation of the rate of local recurrence and distant metastasis in relation to prognostic factors histological, laboratory, clinical and instrumental factors;
Trial Locations
- Locations (1)
Istituto Ortopedico Rizzoli
🇮🇹Bologna, Italy